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Abstract 
Fragment-based drug discovery (FBDD) is a highly interdisciplinary field, rich in integrating ideas from 
pharmaceutical sciences, chemistry, biology and physics, amongst others. Enriching our understanding of 
the fields development, we employed bibliometric techniques to analyze 3,642 publications in FBDD, 
complementing accounts by key practitioners. Mapping its core papers, we find the transfer of knowledge 
from academia to industry. Co-authorship analysis shows that university-industry collaboration has grown 
over time. Moreover, we show how ideas from other scientific disciplines were integrated into FBDD 
paradigm. Keyword analysis show the fields organization into four interconnected practices: library 
design, fragment screening, computational methods and optimization. This study highlights the 
importance of interactions among various individuals and institutions from diverse disciplines in newly 
emerging scientific fields. 
Introduction 
Fragment-based drug discovery (FBDD) is now a widely adopted approach to lead discovery [1,2]. The 
fields origin can be traced back to its first demonstration 20 years ago at Abbott Laboratories by Shuker, 
Hajduk, Meadows and Fesik [3].  The historical development of FBDD has been discussed as anecdotes, 
for example  during lectures at various conferences [4] and in scientific publications [5,6].  The technical 
aspects of the approach have also been described in key reviews [79]. Still, there are insights to be 
learned by systematically studying how the field has developed. In this paper, we look at the 
organizational and social aspects of FBDDs development by analyzing scientific publications that 
describe new developments in the FBDD field and the references that are provided in those publications. 
To analyze these records, we employ bibliometrics, an approach in information sciences to analyze the 
relationship among written publications. 
In the past, technological breakthroughs have resulted from scientists working together at the interface of 
diverse disciplines, recombining knowledge from various fields [10]. FBDDs emergence can be seen as 
various scientific fields coming together: computational methods, molecular biology and medicinal  
chemistry. With pharmaceutical sciences being more multidisciplinary and the pharmaceutical industry 
seeking more collaborations especially in pre-clinical development [1113], it is appealing to investigate 
the drivers that made FBDD so successful. With the increasing interest of how organizational factors can 
enable drug discovery [14], we seek to understand the roles of various groups from industry and academia 
in the rise of FBDD. By tracing how each publication from academia and industry influenced the field, 
we can better understand the role of each institution in driving forward new innovations. 
Finally, looking at the trends in keyword usage in the publications over time and identifying which 
keywords usually go together in these publications can lead to a better grasp of how the field is organized. 
More importantly, by looking at how each keyword trend over time, we can get a sense of how the focus 
of FBDD changed over time and what its current direction is. 
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Data and Methods 
The papers analyzed in this study were downloaded from Thomson-Reuters Web of Science (WOS). In 
order to collect an initial set of papers in the field of fragment based drug discovery, keywords (see Fout! 
Verwijzingsbron niet gevonden.) were used. 
 
Figure 1. Data Collection for FBDD Publications 
 
The keyword search generated 3,208 papers. To ensure that the keyword fragment was used to refer to 
the field, we looked at the abstract, title and keywords fields of the publications and tallied the phrases 
that co-occurred the most with fragment. We removed the combinations that were unrelated to the field, 
resulting to a dataset of 2,781 papers. To verify whether these papers were representative of FBDD, we 
inspected the dataset and found that key publications in the field were not captured by the keywords used 
in the preliminary search. Examples include Hopkinss paper on ligand efficiency [15] and Hanns paper 
on molecular complexity [16], as these have not mentioned any of the used keywords (see Fout! 
Verwijzingsbron niet gevonden.). Thus, an additional data collection step was performed. Using the first 
set of papers, we checked for their most cited references. Analyzing the references, we identified 861 
additional publications that were cited at least 10 times. It is important to note that this list contains some 
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publications that may not be directly related to FBDD development but nevertheless helped to shape the 
field. An example is the many references to Bermans publication describing the Protein Data Bank 
(PDB) that marks the pivotal role of protein structural information in FBDD [17]. Merging these 
publication lists resulted in a total number of publications of 3,642 that span the years from 1953 to 2016.  
In order to understand the development of FBDD, we set the hallmark publication of Shuker, et al[3] in 
1996 as the starting point of our analysis. We analyzed papers in the dataset that were published from 
1996-2016 in intervals of 5-years. Various analyses were done to show the role of prior scientific 
knowledge in adjacent fields and of university-industry collaborations in the development of the field. 
First, the most cited articles in our dataset of FBDD articles were identified  to find the core papers in 
FBDD. For further analysis, we used the software CitNetExplorer [18] to map the top 100 cited papers, 
showing the citation relationship among them, allowing us to trace the evolution of knowledge. To study 
how collaboration between academia and industry evolved in the last 20 years, we generated co-
authorship network maps using the software VosViewer [19]. In an effort to uncover the scientific roots 
of FBDD, we also analyzed the scientific field that the FBDD articles belonged to. Moreover, cluster 
analysis of keywords was performed. By plotting a network map of keywords that co-occur in 
publications, we are able to identify the disciplines that researchers study.  
 
Results and Discussion 
Emergence as Fragment-based Drug Discovery 
The fragment-based approach to drug development is widely recognized to have started in 1996 with its 
first demonstration at Abbott Laboratories [3]. This seminal paper referred to the approach as Structure-
Activity Relationship by Nuclear Magnetic Resonance (SAR by NMR), for the first time demonstrating 
the detection, ranking and progressing of small and weak affinity binders.  
In our analysis, the FBDD publications in the first five years would mostly operate under the general 
umbrella of drug discovery instead of distinguishing itself as a particular discipline. However, traces of 
the keywords related to fragment-based drug discovery has already been present as early as the  nineties, 
for example in the computational work of Joseph Moon and Jeffrey Howe [20] at Upjohn, Sergio Rotstein 
and Mark Murcko [21] at Vertex, and Hans-Joachim Böhm [22] at BASF. Synonyms such as needles and 
needle screening, used to describe early applications by Böhm and co-workers, now at F. Hoffmann-La 
Roche [23], were not adopted by the scientific community as these keywords were used in less than 5 
publications in any year. As seen in Fout! Verwijzingsbron niet gevonden., It would take a few more 
years before research in the field would come together in a term such as fragment-based drug discovery’,  
first appearing in the abstract of the 2002 paper of Murray and Verdonk [24]. Even in those days, the field 
would alter between the keywords lead and drug. The term lead discovery would dominate in the early 
years, stimulated by influential reviews coming from Astex [2527] in the mid-2000s.  Differentiating 
between the two, the term lead emphasizes the early stage wherein fragments are used (for example, 
before pharmacokinetic properties are being considered). On the other hand, the term drug can be helpful 
in that it contextualizes the ultimate goal that fragments aim to achieve, and that is to develop drugs.  


2

By 2009, the term fragment-based drug discovery would finally overtake as the top keyword that 
researchers used to identify the field while lead discovery has lost favor back from its peak in 2005 as 
shown in Fout! Verwijzingsbron niet gevonden..  As it currently stands, the field is still divided 
between drug discovery and drug design. Discovery refers more to the finding of a new drug or drug 
candidate, while drug design puts more emphasis on the rational approaches to build the new drug 
(candidate).  As it is, the abbreviation FBDD is now being  drug discovery has been favored to drug 
design, being used as much as 3 times more in 2016 according to the Web of Science, although the 
different words seem to be used as synonyms.  
 
 
Figure 2. Occurrence of FBDD umbrella keywords in the literature. These keywords were chosen as these 
were the terms used to refer to the field in various important reviews. 
 
Aside from the more extensive keyword use, the growth of the field is shown by looking at the increase in 
number of publications (Table 1). From an initial number of 277 publications in its first five years, this 
has now increased six-fold to 1709 publications from 2011-2016. There has also been an increase in the 
number of unique institutions, authors and countries associated with the field, clearly indicating that the 
approach is being adopted by an increasing number of scientists. 
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Table 1. Summary of the FBDD dataset from 1996-2016 
 1996-2000 2001-2005 2006-2010 2011-2016 
Publications 277 496 939 1709 
Journals  95 143 220 363 
Researchers (min. 5 publications)a 102 190 343 389 
Organizations (min. 10 publications)a     
Academia 1 4 15 53 
SMEs 0 3 3 6 
Big Pharma  1 7 7 7 
a Threshold needed to be set as some firms and researchers may co-author publications but not necessarily practice FBDD 
 
From Ideas to Application: The Role of Industry 
Clearly, the industry has played a pivotal role in developing FBDD. Although the approach was first 
demonstrated at the big pharmaceutical firm Abbott Laboratories [3], other organizations in the private 
sector were instrumental in subsequent FBDD development, in particular by improving emerging 
technologies and approaches to allow application in drug discovery. In the first few years of the field,  
majority of articles were coming from the industry. This is noteworthy because an inherent bias towards 
universities is expected when focusing on scientific publications, due to the incentive of academia to 
publish.
. 
Considering that the  industry has the opposite incentive of withholding information for 
competitive advantage [28,29], it emphasizes how influential the industry was in the development of 
FBDD.  
This is also supported by looking at the top institutes in terms of scientific impact, as measured by 
citations. As seen in Table 2, especially for the first years of FBDD, the industry clearly led the field. 
Abbott Laboratories dominated in the late nineties. Astex (founded in 1999 by University of Cambridge 
professors Tom Blundell and Chris Abell and former head of structural biology and bioinformatics of 
GlaxoWellcome dr. Harren Jhoti) led in the next decade. Only in the recent five years would there be a 
surge in publications from the academia in the top 10 list. Table 2 also shows that biotech companies such 
as Astex, Vertex and Sunesis have played an important role in establishing the field. However, it is also 
important to note that some prominent biotechs and pharmaceutical companies in FBDD do not show up 
in this particular analysis as they might have put less emphasis on authoring scientific publications. 
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Table 2. Top institutional publishers and their total citations in the field of FBDD over time a  
Rank 1996-2001 2001-2006 2006-2011 2011-2016 
1 Abbott Labs 154 Astex 368 Astex 595 Univ Oxford 368 
2 Vertex 77 Abbott Labs 221 Abbott 320 Univ Cambridge 348 
3 Univ California 
San Francisco 
52 Sunesis 187
Univ California 
 San Francisco 
261 Glaxosmithkline 304 
4 Roche 49 Novartis 163 Astrazeneca 249 Astex 232 
5 Novartis 43 Pfizer 139 Univ Cambridge 216 Univ California San 
Francisco 
156 
6 Univ Sheffield 35 Scripps Inst 112 Novartis 188 Astrazeneca 139 
7 BASF 34 Astrazeneca 93 Scripps Inst 187 Heptares 120 
8 Univ of California  San 
Diego 
29 Glaxosmithkline 90 Glaxosmithkline 184 Pfizer 110 
9 Univ Marburg 28 Sanford Burnham 87 Pfizer 155 Cancer Research UK 105 
10 CCDC 26 Univ California 
 San Francisco 
85 Vernalis 135 Univ Dundee 104 
a Industry groups in red 
The important role that the private sector has played in FBDD innovation is also apparent when looking at 
the top 10 cited papers from our collection of FBDD papers (Table 3). A staggering number of nine of the 
ten top publications were written by industry researchers. The only paper in the top 10 coming from 
academia is Bermans publication on the Protein Data Bank [17], which does not strictly belong to FBDD 
but is a fundamental resource for drug discovery research in general and for FBDD in particular as many 
of the hit fragment optimization programs have been guided by protein structural data. Next to some 
influential reviews, including work from Hajduk, Congreve, Rees (all from Astex) and Erlanson (at that 
time working for Sunesis Pharmaceuticals), the conceptual Ligand Efficiency (LE) work of Hopkins and 
co-workers (at that time working for Pfizer) has made enormous impact (rank 2, Table 3).  LE assesses 
the contribution of every atom on the affinity of the ligand and is being used to select the most promising 
fragment hits and to guide the growing of the fragments into bigger drug-like molecules. Also, the 
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theoretical work of Hann and co-workers at Glaxosmithkline (rank 6, Table 3) on understanding how 
molecular complexity impacts hit finding has been influential for FBDD. Amongst others, this work 
raised the realization that fragments should be simple and small molecules that can interrogate the binding 
sites with higher resolution. Amongst others, this has resulted in the guidelines captured in the Rule of 
Three that define quality fragments. This popular mantra was attractively pitched by Congreve and co-
workers (ranked 4) as a variation on Lipinskis Rule of Five (ranked 7, Table 3) that defines the properties 
of soluble and permeable drug-like molecules, the ultimate goal of FBDD efforts.    
Table 3. The ten most cited papers in the dataset of FBDD articlesa 
Authors Title Journal Affiliation Year Cit
1 Shuker, SB; Hajduk, PJ;  
Meadows, RP; Fesik, SW 
Discovering high-affinity ligands for proteins: SAR by 
NMR 
Science Abbott Labs 1996 454
2 Hopkins, AL; Groom, CR;  
Alex, A 
Ligand efficiency: a useful metric for lead selection Drug 
Discovery 
Today 
Pfizer 2004 403
3 Hajduk, PJ; Greer, J A decade of fragment-based drug design: strategic 
advances and lessons learned 
Nature 
Reviews Drug 
Discovery 
Abbott Labs 2007 353
4 Congreve, M; Carr, R;  
Murray, C; Jhoti, H 
A rule of three for fragment-based lead discovery? Drug 
Discovery 
Today 
Astex 2003 342
5 Congreve, M; Chessari, G;  
Tisi, D; Woodhead, AJ 
Recent developments in fragment-based drug 
discovery 
Journ of 
Medicinal 
Chemistry 
Astex 2008 290
6 Hann, MM; Leach, AR; 
 Harper, G 
Molecular complexity and its impact on the 
probability of finding leads for drug discovery 
Journ Chem 
Info and Comp 
Sci 
Glaxosmithkline 2001 287
7 Lipinski, CA; Lombardo, F; 
Dominy, BW; Feeney, PJ 
Experimental and computational approaches to 
estimate solubility and permeability in drug discovery 
and development settings 
Advanced 
Drug Delivery 
Reviews 
Pfizer 1997 286
8 Rees, DC; Congreve, M;  
Murray, CW; Carr, R 
Fragment-based lead discovery Nature 
Reviews Drug 
Discovery 
Astex 2004 275
9 Berman, HM; Westbrook, J; Feng, 
Z; Gilliland, G; Bhat, TN; Weissig, 
H; Shindyalov, IN; Bourne, PE 
The Protein Data Bank Nucleic Acids 
Research 
Rutgers Univ  
NIST 
Burnham Inst 
UCSD 
2000 257
10 Erlanson, DA; McDowell, RS; 
O'Brien, T 
Fragment-based drug discovery Journ of 
Medicinal 
Chemistry 
Sunesis 2004 219
a Industry groups in red 
 
However, if we look at the top cited journals in the recent years (Table 4), seven out of the 10 most cited 
publications were authored by academia from 2009. This adoption by academia is validated as well by the 
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increase in the share of publishing universities and research institutions in FBDD in the last five years. 
One of the factors for the adoption by academia is the rise of academic medicinal chemistry and drug 
discovery groups [11,30]. We can also speculate on the mobility of researchers, including experts from 
industry that move towards university, setting up academic drug discovery research groups. As there has 
been an increase of interest in how researcher mobility affects innovation [31], the impact of this mobility 
and transfer of knowledge in FBDDs development will be the topic of future research. 
Table 4. The ten most cited papers published from 2009 in the dataset of FBDD articles. 
Authors Title Journal Affiliation Year Cit 
1 Murray, CW 
Rees, DC 
The rise of fragment-based drug discovery Nature Chemistry  Astex  2009 141 
2 Chessari, G 
Woodhead, AJ 
From fragment to clinical candidate-a 
historical perspective 
Drug Discovery Today  Astex  2009 82 
3 Murray, CW 
Verdonk, ML 
Rees, DC 
Experiences in fragment-based drug 
discovery 
Trends In Pharmacological 
Sciences 
 Astex  2012 76 
4 Scott, DE 
Coyne, AG 
Hudson, SA 
Abell, C 
Fragment-based approaches in drug 
discovery and chemical biology 
Biochemistry  Univ Cambridge 2012 75 
5 Murray, CW 
Blundell, TL 
Structural biology in fragment-based drug 
design 
Current Opinion In Structural 
Biology 
Univ Cambridge 
Astex  
2010 70 
6 de Kloe, GE 
Bailey, D 
Leurs, R 
de Esch, IJP 
Transforming fragments into candidates: 
small becomes big in medicinal chemistry 
Drug Discovery Today IOTA  
Vrije Univ Amsterdam 
2009 69 
7 Filippakopoulos,P 
Bradner, JE et al. 
Selective inhibition of BET bromodomains Nature Dana Farber Cancer 
Inst 
Harvard Univ 
Univ Notre Dame 
Univ Oxford 
 
2010 68 
8 Baker, M Fragment-based lead discovery grows up Nature Reviews Drug 
Discovery 
 2013 67 
9 Emsley, P 
Lohkamp, B 
Scott, WG 
Cowtan, K 
Features and development of Coot Acta Crystallographica 
Section D-Biological 
Crystallography 
Karolinska Inst 
Univ York 
UC Santa Cruz 
Univ Oxford 
2010 67 
10 Chen, Y 
Shoichet, BK 
Molecular docking and ligand specificity in 
fragment-based inhibitor discovery 
Nature Chemical Biology  UC San Francisco 2009 62 
 
Knowledge Transfer: The Role of University-Industry Collaboration  
We then explored the list to the top 100 cited articles in FBDD, representing the core papers of FBDD. By 
creating a citation map of these articles over time, we can visualize the evolution in ideas within FBDD 
and the changing roles of industry and academia in shaping these ideas. Whereas Table 2 and Table 3 
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reveal the dominating role of the industry in establishing FBDD, the plot in Fout! Verwijzingsbron niet 
gevonden. reveals that ideas and tools developed in academia provided groundwork for the field.  
.  
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Figure 3. Citation map of 100 core papers in FBDD. Each paper is labelled by its last author. The colors 
reflect the affiliation of the authors Square highlights mark review articles. 
Most of the theoretical grounding of FBDD came with ideas from the academia as early as 1970s. This 
early influence by the academia can be seen explicitly with the paper of Jencks from Brandeis University 
[32]. In his paper on the additivity of binding energies, he puts out the idea that large molecules can be 
considered as a combination of fragments.  
On the upper left side of the citation map, a number of papers authored in the academia can also be seen. 
These are foundational publications about influential drug discovery tools such as the Protein Data Bank 
in 1977 [33], molecular docking approaches by Ferrin and co-workers in 1982 [34], the molecular 
modelling software CHARMM by Karplus and co-workers in 1983 [35] and Goodfords computational-
procedure for determining energetically favorable binding-sites in 1988 [36] and functionality maps of 
binding sites by Karplus et al. in 1991 [37]. Also other computational chemistry efforts (e.g., Karplus, 
Schneider, Hubbard) to develop de novo structure generation and molecular docking software have made 
a tremendous impact. Frequently, the developed algorithms use fragment-based approaches as 
computational tricks to  dissect the complication of having to assess and weigh the various properties of 
bigger, drug-like compounds. In those early nineties, the technologies and protocols to determine 
fragment binding to proteins, using for example sensitive biophysical technologies, were not yet 
available. The computational approaches were also adopted by industry, for example by Schneider at 
Roche and both Klebe and Böhm at BASF. The latter scientist also contributed to the pioneering needle 
screening work at Roche (vide supra) that combines in silico approaches with biochemical and 
biophysical screening as an early example of fragment-based approaches in hit finding and lead 
development. The impact of Abbott Laboratories in developing the applications is not only apparent from 
the work of Fesik and co-workers with NMR technology, also the work of Greer and co-workers that 
focusses on discovering ligands using X-ray crystallographic screening. Later, their crystallographic 
screening method called CrystaLEAD) was further developed and exploited by influential scientists like 
Hubbard (University of York, Vernalis), Rees, Jhoti (Astex), Abell, Blundell (University of Cambridge, 
co-founders of Astex). These high throughput X-ray crystallographic screening efforts were supported by 
academic activities such as the development by Cowtan and co-workers of the software COOT, a program 
that is used to display electron density maps and atomic models.  
With academia laying out FBDDs foundations and Big Pharma first demonstrating the technique in 
1996, the road was now ready for the fields valorization. The next decade of key FBDD publications 
would almost exclusively come from the industry. Especially in the early 2000s, smaller structure-based 
drug discovery companies like Astex, Vertex and Sunesis come to play an important role. These biotechs 
specialized in specific FBDD technologies and approaches (e.g., crystal soaking, biochemical assays, 
tethering) and perfected them for application in hit finding and lead generation. Fragments provided a 
way for these companies to obtain hits without the need to invest millions in compound libraries and 
robotics that are needed for typical high-throughput screening (HTS) approaches [6]. It is noted that not 
all known technologies and FBDD companies do appear in this bibliometric analysis, possibly because 
their restricted efforts to publish in scientific literature. It is interesting to see that those companies that do 
publish make an significant impact when considering collaborations that publish FBDD work (Fout! 
Verwijzingsbron niet gevonden.).  
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In the early years of FBDD, the majority of institutions involved were carrying out research 
independently. In this period, only a small group of mostly academic institutions were collaborating with 
a few players in the industry (Fout! Verwijzingsbron niet gevonden.a). This is seen by mostly 
fragmented nodes on the right side of the plot.  
However, by the early 2000s, a network of university-industry collaborations started to form (Fout! 
Verwijzingsbron niet gevonden.b). With the research in FBDD becoming more collaborative, 
institutions from big pharma, spinoffs and academia coauthored more and more articles together. 
Especially in the final period from 2011-2016, a greater degree of integration among practicing 
institutions can be observed. The tight integration shows that FBDD is a high-tech and multidisciplinary 
research field in which specialists in various research area collaborate in developing new pharmaceuticals. 
It is noted that the development of this field also coincides with the transition of the pharmaceutical 
landscape in which the big companies outsource more in their pre-clinical research [38,39], an important 
change that seems to have shaped the FBDD field. 
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Figure 4. Collaboration network map of top 500 publishing institutions in FBDD grouped in five year 
periods from 1996-2016. Each node corresponds to an institution. The size reflects the number of 
publications. Red nodes are from academia while blue nodes are from industry. Dark blue nodes are from 
big pharma while light blue are other industrial firms including small biotechs and firms from adjacent 
industries. For years 2006-2016, the biggest cluster is shown 
Recombining Knowledge from Other Scientific Fields 
To further understand how FBDD integrates knowledge from various scientific disciplines, we manually 
classified the previous core papers according to their content and discipline of origin as seen in Fout! 
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Verwijzingsbron niet gevonden.. 
 
Figure 5. Citation map of 100 core papers in FBDD. The colors show clustering of papers by similarity. 
Before 1996, the scientific groundwork that would eventually be integrated in FBDD would come from 
two separate fronts. As seen on the upper right side of Fout! Verwijzingsbron niet gevonden., on one 
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end, we have the work of Jencks which provided the theoretical rationalization for fragments. On the 
other end (green cluster of Fout! Verwijzingsbron niet gevonden.),  the previously discussed 
methodologies, that are fundamental in FBDD research can be seen. These computational approaches 
form an independent branch that used fragment approaches in binding energy calculations and de novo 
structure generation software. As seen in Fout! Verwijzingsbron niet gevonden., there is a clear 
separation between these two branches with no paper citing the two, prior to Fesiks hallmark publication.  
Thus, it shows how key the SAR by NMR Science paper by Fesik and co-workers was in jumpstarting the 
field. As shown in Fout! Verwijzingsbron niet gevonden., the paper serves as a hub where a dense 
amount of publications branch from. The publication of Fesik brought the two separate branches together, 
explicitly referring to the paper of Jencks while also referring to Bohms LUDI [22], Hubbards HOOK 
[40] and Murckos GroupBuild [21] at the same time. By this, the theoretical considerations and the 
computer-aided drug design capabilities were combined, enabled by the emerging biophysical screening 
technologies (e.g., NMR) and combined with X-ray crystallography to respectively measure and visualize 
low affinity fragment binding.   
We looked at the categories of the journal sources of FBDD papers. Doing so allows us to see the 
disciplines that FBDD was building from. In Fout! Verwijzingsbron niet gevonden., before 1995, 
FBDD literature cited articles coming from the fields of biophysics, biochemistry and molecular biology 
and computer science. This signals that advancements in knowledge in these various fronts was necessary 
for FBDD to expand. It also gives a clear indication that FBDD is going mainstream with many 
publications now appearing in the more applied Medicinal Chemistry field, whereas in the early years 
most papers where in the field of biochemistry & molecular biology, biophysics and computational 
chemistry. 
 
Figure 6. Categories of journals over time 
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Although this cluster includes the pre-90s computational techniques described before, the influence of 
this cluster extends into the early 2000s, including  de novo structure generation and docking algorithms 
such as Glide[41] in 2004 and development of frequently used databases such as ZINC [42] in 2005. 
Referring back to Fout! Verwijzingsbron niet gevonden., the blue cluster on the right side is composed 
of what is considered as integral FBDD publications. These include principles and demonstrations of how 
various biophysical techniques can be used in the paradigm of FBDD. Included as well are applications of 
FBDD to various therapeutic targets, i.e., the actual use in drug discovery [43,44]. Moreover, it also 
includes 16 key reviews that summarize and integrate knowledge in the field.  
We also see a violet cluster at the early stages of FBDD from 1996-2002, which describes concepts on the 
molecular basis of the approach. One way of interpreting this is that there are researchers (like Fesik) who 
bridge the gap between a new field and established methods. In this case, they provided the molecular 
basis of FBDD. By formulating principles from their outsider perspective, they are able to integrate 
previously unexploited knowledge and technologies to the growing body of FBDD literature. The 
important role of key opinion leaders can be seen in the central part of the plot, where around 2005 
scientists like Rees, Jhoti, Abell (Astex and University of Cambridge), Hubbard (University of York, 
Vernalis), Fesik, Hajduk (Abbott Laboratories) and Erlanson (Sunesis) explicitly integrate the various  
 
Figure 7. Occurrence of various techniques in FBDD papers over time aspects of FBDD in their 
publications.     
The citation map also shows an orange cluster that was integrated into FBDD relatively more recently. 
These are papers in the field of crystallography such as the CCP4 suite[45] in 1994, Minors processing 
of X-ray diffraction data[46] and Dodsons refinement of macromolecular structures[47] both in 1997.  
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The impact that crystallography would bring to FBDD carries on today. By analyzing the keywords used 
in the abstract and title of the publications in the field, we can get a sense of the methods that catch the 
interest of practitioners. As seen in  Fout! Verwijzingsbron niet gevonden., although nuclear magnetic 
resonance has been the dominant technique in the first years of FBDD, it has been replaced by x-ray 
crystallography in the last five years. It is important to note that this does not perfectly reflects the usage 
of such techniques in various laboratories but rather reflects the identifiers that are used by authors to 
attract their targeted readership.  
Today, the field is organized into four interrelated practices. To come up with these four classifications, 
the top keywords in FBDD was plotted and clustered according to how often they occur together per 
paper (Fout! Verwijzingsbron niet gevonden.). Four clusters were detected, corresponding to the four 
major interrelated activities in FBDD  designing the fragment library, screening them using for example 
biophysical techniques, modeling using computational methods and optimizing the lead. Although the 
position of the keywords generally indicate the category and interrelatedness of the keywords with each 
other, the position must be taken with a grain of salt as keywords are more often than not related to the 
three other dimensions of FBDD.  
In order to see what the trends have been in FBDD in the years, these keywords were colored according to 
the average year of publication. As seen in Fout! Verwijzingsbron niet gevonden., the colors 
correspond to the average year of keyword occurrence. Interestingly, there is a trend towards the upper 
left cluster of molecular biology, with more keywords occurring more recently. This is expected as the 
field has been moving towards applying FBDD, instead of building basic knowledge that comes from the 
other clusters. 
As FBDD matures, it has been applied to more targets. This can be seen by the curious case of publication 
of Bradner [48]. Going back to Fout! Verwijzingsbron niet gevonden., this publication does not cite the 
core FBDD literature yet is cited by a lot of the recent papers in FBDD. This publication on the inhibition 
of BET bromodomains has been an area of interest for FBDD researchers in the recent years.  
Together with other targets, the focus now for FBDD has been its application. The most cited references 
in the recent years (as seen in Table 4) have been reviews showing how more and more leads originating 
from FBDD are entering the clinical trials. Not only industry is using the technique, but also various 
academic groups. As Baker [2] puts it on a news article in 2013, FBDD has indeed grown up.  
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Figure 8. Occurrence network of top 100 keywords in FBDD. Color correspond to  average year of 
occurrence of keyword 
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Conclusions 
In our paper, we have shown the history of FBDD through bibliometric methods. In the early days of the 
field, research in FBDD was highly fragmented, operating under the general umbrella of drug discovery. 
Today, scientific progress in FBLD and FBDD are organized with the leading keywords fragment-based 
lead discovery,  fragment-based drug discovery and fragment-based drug design. Although all these 
terms refer to the same approaches, they put emphasis on different aspects of work and the ultimate aim 
of the endeavors.  
The history of FBDD provides a solid case on how recombining knowledge from various worlds can 
advance science. This was seen in two levels. First, on the organizational level, industry and academia 
played their respective roles reliably well. Academia laid down the theoretical foundations and also 
generated research on methods that can be later implemented industrially. With the basic science laid out, 
industry was able to valorize the knowledge and integrate them in actual drug discovery efforts. Progress 
in FBDD was able to occur alongside a growing interconnected network of collaborations among various 
institutions. The studies clearly identify an increasing interconnectedness between academia and industry. 
Interestingly, FBDD research field has developed in the same years that the pharmaceutical research 
landscape was undergoing major changes, with the big pharmaceutical companies outsourcing more and 
more pre-clinical research work [49]. As such, FBDD forms an interesting topic to further explore 
business development and innovation management in the pharmaceutical sciences. Using the bibliometric 
database as a premise, we would like to deepen the knowledge on how collaborations are formed. Also, 
with collaborations in FBDD being increasingly created, it is of value to understand how these 
collaborations are maintained so that all the complementary abilities of each partners are synergized 
instead of working separately. Finally, it is of essence to evaluate the success of these initiatives towards 
open innovation.  
The technical aspect of FBDDs development show us that integration of outsider technologies with solid 
theoretical grounding is a useful approach to innovation. Being able to spot opportunities for integrating 
is  becoming a more valuable skill for researchers wanting to stay on top of their fields. It is of interest 
then to understand how both academia and industry cope with this need. Further surveys should be done 
on this front.  
Future studies can address the limitations of our current approach. In this bibliometric analysis, we only 
focused on scientific publications in FBDD. This analysis has identified the key opinion leaders of the 
field and clearly, publications that are accessible for the world-wide research community make an 
obvious impact. However, certain key contributions to the FBDD field are excluded from the analysis. As 
pharmaceutical companies and biotechs are often not incentivized to publish, analyzing the patent 
landscape might be able to characterize better the current state of collaborations in the field. Collecting 
additional data sources such as companies disclosures, conference attendance and new chemical entities 
in the market could provide a comprehensive picture on the growth of FBDD. By connecting and 
analyzing these data together, it would be possible to better understand the factors that allow companies 
to successfully bring their laboratory results towards the market. We believe that building a better 
understanding of business development and innovation management in such a well-defined and recently 
developed research area as FBDD offers useful case studies to describe the changing landscape of 
pharmaceutical sciences.   
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